Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

NCT07076212 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Pancreatic Adenocarcinoma
Locally Advanced Pancreatic Adenocarcinoma

Interventions

DRUG: Liposomal Irinotecan
DRUG: Oxaliplatin
DRUG: 5-Fluorouracil
DRUG: Leucovorin
DRUG: Gemcitabine (mg/m²)
DRUG: Nab-paclitaxel
DRUG: Cisplatin

Sponsor

Medical University of South Carolina